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Summary
 
Human cytomegalovirus (HCMV), a betaherpesvirus, has developed several ways to evade the
immune system, notably downregulation of cell surface expression of major histocompatibility
complex class I heavy chains. Here we report that HCMV has devised another means to com-
promise immune surveillance mechanisms. Extracellular accumulation of both constitutively
produced monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor–superin-
duced RANTES (regulated on activation, normal T cell expressed and secreted) was downreg-
ulated in HCMV-infected fibroblasts in the absence of transcriptional repression or the expres-
sion of polyadenylated RNA for the cellular chemokine receptors CCR-1, CCR-3, and
CCR-5. Competitive binding experiments demonstrated that HCMV-infected cells bind
RANTES, MCP-1, macrophage inflammatory protein (MIP)-1
 
b
 
, and MCP-3, but not MCP-2,
to the same receptor as does MIP-1
 
a
 
, which is not expressed in uninfected cells. HCMV en-
codes three proteins with homology to CC chemokine receptors: US27, US28, and UL33.
Cells infected with HCMV mutants deleted of US28, or both US27 and US28 genes, failed to
downregulate extracellular accumulation of either RANTES or MCP-1. In contrast, cells in-
fected with a mutant deleted of US27 continues to bind and downregulate those chemokines.
Depletion of chemokines from the culture medium was at least partially due to continuous in-
ternalization of extracellular chemokine, since exogenously added, biotinylated RANTES ac-
cumulated in HCMV-infected cells. Thus, HCMV can modify the chemokine environment of
infected cells through intense sequestering of CC chemokines, mediated principally by expres-
sion of the US28-encoded chemokine receptor.
Key words: RANTES • human cytomegalovirus • chemokine receptors • sequestration • 
monocyte chemoattractant protein 1
 
E
 
fficient control of persistent viral infections relies on
the specific recognition of viral antigens by T lympho-
cytes and/or NK cells. These cells are activated by inflam-
matory cytokines. However, once activated they must be
mobilized to the sites of infection. Such mobilization de-
pends on the creation of gradients of chemokines that not
only chemoattract effector leukocytes, but also play a sup-
plementary role in stimulating the effector mechanisms of
these cells once they are targeted to sites of infection (1).
Numerous viruses persist in host organisms for the re-
mainder of the individual’s life. This persistence requires
the virus to be able to evade eradication by the immune
system and reflect a co-evolution of the infectious agent
with its host. A number of viruses have developed a variety
of mechanisms for immune evasion (2–5). Some of these
viruses confer lifelong immunity, as assessed by persistent
immunological markers of primary infection, without com-
plete eradication of the virus in question. To accomplish
this feat, they have acquired genes that mimic host genes
involved in the immune response (for review see references
in 5, 6) and have products that can interfere with numerous
host cell defense mechanisms (complement activation, in-
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terferon inhibition, antibody recognition, growth factors
and cytokines, etc.)
Notable among such persistent viruses are the herpesvi-
ruses (2, 4, 7). After primary infection, these viruses be-
come permanent residents of their hosts. In the majority of
cases, primary infection is clinically inapparent. Pathophys-
iological manifestations are only apparent upon immuno-
depression of the host, whether natural (pregnancy), iatro-
genic (organ transplantation), or acquired (infection with
HIV). From a purely virological point of view, this implies
that these viruses have developed a low profile as concerns
the immune system.
Herpesviruses are among the largest viruses known. Their
genomes have the capacity to encode from 80 to 
 
.
 
200
proteins (7). They have evolved with their hosts for mil-
lions of years (8). The target cells of viral latency are some-
times very limited, for instance for herpes simplex virus
(neurons) and Epstein-Barr virus (B lymphocytes). Latency
targets of viruses like CMV (9–11), appear much broader.
In this case, the virus has probably adopted multiple strate-
gies for evading immune surveillance, since it resides in a
variety of functionally different cell types.
Human CMV (HCMV),
 
1
 
 a betaherpesvirus, has devel-
oped a number of strategies which may limit its recognition
by the host’s immune system and its eradication. It induces
expression of Fc receptors (12–15) and upregulates expres-
sion of complement regulatory proteins CD55 and CD46
(16), and incorporates CD55 and CD59 into the virion en-
velope (17). The HCMV genome also contains a number
of genes that code for factors capable of interfering with
immune surveillance. Most renowned are the four genes
(US2, US3, US6, and US11) that code for proteins that
prevent presentation of HLA class I molecules at surface of
infected cells (18–23). HCMV also encodes its own HLA
class I–like molecule that recently has been shown to act as
a decoy for NK cells (24, 25). Finally, HCMV virus poten-
tially encodes a protein homologous to the variable and
constant regions of the TCR-
 
g
 
 chain (UL20) (26), the
function of which has yet to be determined.
In addition to the aforementioned genes, HCMV pos-
sesses three genes, designated UL33, US27, and US28, that
encode proteins homologous to the seven transmembrane
domain CC chemokine receptors (27, 28). To date, only
one of these receptors, US28, has been shown to be a func-
tional CC chemokine receptor (29, 30).
In this study, we explored the functionality of US28 and
US27 in the context of HCMV-infected cells and we show
that constitutively produced or cytokine-superinduced CC
chemokines are depleted from infected cell medium. Our
data suggest that the HCMV-encoded US28, and perhaps
 
US27, G protein–coupled receptor homologues have a role
in this process. The results indicate that HCMV has devised
another strategy that may play a role in immune system
evasion by reducing the availability of host chemokines.
 
Materials and Methods
 
DNA Sequence. 
 
The nucleotide numbering system of Chee
et al. (28) was used for the HCMV strain AD169 DNA sequence
(available from EMBL/GenBank/DDBJ under accession number
X17403).
 
Cells.
 
Human foreskin fibroblast (HFF) cells and human dip-
loid lung fibroblast (MRC-5 and WI-38) cells were used in this
study. All cells were grown in DMEM containing 5–10% FCS.
Cells were consistently negative for mycoplasma.
 
Virus.
 
The AD169 strain of HCMV was used throughout as
wild-type HCMV and as the parent strain for the development of
the recombinant mutant viruses described below. A low passage
HCMV clinical strain and simian CMV were provided by J. Nel-
son (Oregon Health Sciences University, Portland, Oregon) and
W. Gibson (Johns Hopkins University School of Medicine, Balti-
more, MD), respectively. Viral growth, titering, and the produc-
tion of stocks in fibroblasts have been described previously (31).
Mutant viruses were derived by insertion of a 2.85-kb 
 
b
 
-gluc-
uronidase (
 
b
 
-gluc) expression cassette (
 
b
 
-gluc is under the control
of the early HCMV 2.7-kb promoter and the herpes simplex vi-
rus type 1 thymidine kinase polyadenylation signal) into cloned
viral target genes and subsequent homologous recombination into
the viral genome, using a strategy described previously (18, 20,
32). Control mutant virus RV134 contains the 
 
b
 
-gluc cassette in-
sert within the US9-US10 intergenic region at base 199,021 (32),
such that no genes or transcription units were interrupted (33).
The 
 
b
 
-gluc cassette insertion in RV91 is at base 218,251, disrupt-
ing the 1.09-kb US27 gene 
 
z
 
0.35 kb from its translation initia-
tion codon. RV92 contains the 
 
b
 
-gluc cassette in place of a 0.20-kb
NH
 
2
 
-terminal region (bases 219,426–219,629), 0.23 kb from
the translation initiation codon of the 1.06-kb US28 gene. The
 
b
 
-gluc cassette insertion in RV101 replaces bases 218,251–
219,629, thereby deleting the 0.74- and 0.43-kb regions of US27
and US28, respectively. Plaques containing 
 
b
 
-gluc–expressing vi-
rus were purified and the proper genomic organization of each
mutant was determined by DNA blot hybridization (32) to reveal
diagnostic BamHI and EcoRI restriction fragment changes. Viral
infections for single cycle growth analyses in HFFs were done at a
multiplicity of infection of 2; total virus yield was assessed from
day 2 to day 7 postinfection (pi), as described previously (32).
 
Measurement of Chemokines.
 
RANTES (regulated on activa-
tion, normal T cell expressed and secreted) and monocyte
chemoattractant protein (MCP)-1 were measured by ELISA us-
ing kits (purchased from Medgénix-Biosources [Rungis, France]
or R&D Biotechnology [Abingdon, UK] for RANTES, and Hy-
Cult Biotechnology [Uden, The Netherlands] and R&D Bio-
technology for MCP-1) according to the manufacturers’ instruc-
tions. Intracellular RANTES was measured in cytosolic fractions
after treatment of cells with acid-glycine (34) buffer for 3 min at
room temperature, trypsinization, and lysis in 10 mM hepes, pH 8,
1 mM EDTA, 50 mM NaCl, 0.5 M sucrose, 0.5% NP-40, 1 mM
PMSF, and 1% digitonin. All results are expressed as picogram of
chemokine per milliliter.
 
Chemokines and Specific Antibodies.
 
Anti–human RANTES and
anti–human MCP-1 were purchased from R&D Biotechnology.
For infected cell binding studies, 
 
125
 
I-labeled MIP-1
 
a 
 
(2,200Ci/
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
-gluc, 
 
b
 
-glucuronidase; Fmoc, fluorenyl-
methyloxycarbonyl; HCMV, human cytomegalovirus; HFF, human fore-
skin fibroblast; MIP, macrophage inflammatory protein; MCP, monocyte
chemoattractant protein; pi, postinfection; RANTES, regulated on acti-
vation, normal T cell expressed and secreted; RANTES-B, biotinylated
recombinant human RANTES; RT-PCR, reverse transcriptase PCR. 
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mmol) was purchased from NEN
 
Ô
 
 Life Science Products (Bos-
ton, MA); unlabeled chemokines MCP-1, MCP-2, MCP-3,
RANTES, MIP-1
 
a
 
, and MIP-1
 
b 
 
were purchased from Pepro
Tech (Rocky Hills, NJ).
 
Biotinylation of RANTES.
 
RANTES was obtained by solid
phase synthesis, using the fluorenylmethyloxycarbonyl (Fmoc)-
chemistry on a fully automated Synthesizer (Applied Biosystems
model 433A; PE Applied Biosystems, Foster City, CA), and bi-
otin was specifically incorporated after completion of the synthe-
sis, according to the protocol described previously (35). Purity
and identity of the product were assessed by analytical HPLC,
capillary electrophoresis, amino acid analysis, and electrospray
mass spectrometry.
 
Chemokine Binding Experiments.
 
All assays were done in 24-
well tissue culture plates containing 
 
z
 
1.5 
 
3 
 
10
 
5
 
 HFF cells per
well as a confluent monolayer. Growth media was removed from
uninfected or virus-infected (multiplicity of infection 2.5) HFF
cells at the desired time. Each well was washed two times with
cold (4
 
8
 
C) PBS. 0.25 ml of cold binding buffer (DMEM contain-
ing 25 mM Hepes and 1 mg/ml BSA) was added to each well.
Where indicated, cold competitor chemokine was added (4 
 
m
 
l
per well) and the plate was incubated at 4
 
8
 
C for 15 min with gen-
tle rocking. Then, 2.5 
 
m
 
l of 
 
125
 
I-labeled MIP-1
 
a
 
 (0.25 nM final
concentration) was added to each well and the plate was incu-
bated at 4
 
8
 
C for 6 h. The media was removed and the monolayer
was washed twice with cold binding buffer, then once with cold
PBS containing 1 mg/ml BSA. 1 ml of extraction buffer (20 mM
sodium phosphate, pH 7.5, with 1% Triton X-100) was added to
each well and incubated at 37
 
8
 
C for 30 min. The extracts were
then counted in a gamma radiation counter (model 1272; LBK;
Valac, Gaithersburg, MD).
 
Immunoblot Analysis.
 
HCMV UL80 protease expression was
assessed by ECL (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, UK) immunoblot analysis using UL80 16K
rabbit polyclonal primary antibody, as described previously (36).
 
Induction of RANTES Production by TNF Treatment of Fibro-
blasts.
 
Fibroblasts were seeded at 10
 
5
 
 cells/well of 24-well
plates. The next day, some cells were infected with HCMV (mul-
tiplicity of infection 5). Where indicated, uninfected or infected
cells were treated with 5 ng/ml TNF-
 
a
 
. TNF-
 
a
 
 treatment of un-
infected and infected cells was continuous for 24, 48, or 72 h.
Culture supernatants were collected at 0–24, 24–48, and 48–72 h
after infection and/or the beginning of treatment, clarified, and
frozen at 
 
2
 
20
 
8
 
C before measuring RANTES. Cells were re-fed
with fresh medium, either with or without TNF-
 
a
 
, depending
on the length of treatment, as indicated in the legend of Fig. 1.
 
Adsorption of RANTES by Infected Cells.
 
Before adsorption, su-
pernatants were collected and cells were washed once with PBS
and then incubated for 3 min at room temperature in acid-gly-
cine buffer (34) to remove residual receptor-bound chemokines.
Cells were washed once again with PBS before incubation with
RANTES. Recombinant human RANTES (rRANTES) at 500
pg/ml was adsorbed to uninfected cells or cells infected for 24,
48, or 72 h after infection at 37
 
8
 
C for time intervals indicated in
Results. Cell medium was then sampled, clarified by centrifuga-
tion at 5,000 rpm for 5 min, and maintained at 
 
2
 
20
 
8
 
C before
measurement of RANTES. The starting RANTES solution was
also frozen.
For internalization of biotinylated-rRANTES (RANTES-B),
48 h after infection with recombinant and wild-type HCMV,
cells were washed and treated with acid-glycine buffer as above,
and then incubated with 100 nM RANTES-B for 3 h at 37
 
8
 
C.
Cells were washed once with PBS, incubated 5 min with glycine-
buffer to remove membrane-bound biotinylated-rRANTES, and
then lysed in high salt buffer (50 mM Tris, pH 8, 300 mM NaCl,
10% (vol/vol) glycerol, 0.5% NP-40, 1% digitonin, and 1 mM
PMSF). Proteins were separated in 15% SDS-PAGE and trans-
ferred to reinforced nitrocellulose (Sartorius, Göttingen, Ger-
many). Blots were saturated with 3% cold-water fish gelatin, 1%
BSA (both from Sigma Chemical Co., St. Louis, MO) in PBS/
Tween 20 (0.1%). Blots were then incubated for 1 h at room
temperature with a 1:300 dilution of peroxidase-labeled streptavi-
din (Amersham Pharmacia Biotech) in the same buffer before be-
ing developed by enhanced chemiluminescence (Super ECL;
Pierce Chemical Co., Rockford, IL).
 
RNA Analysis.
 
Expression of transcripts from HCMV UL33,
US27, and US28 genes were analyzed by RNA blot hybridiza-
tion using riboprobes, as described previously (33). Reverse tran-
scriptase (RT)-PCR was used to examine expression of cellular
chemokines and chemokine receptors. For RT-PCR, RNA was
extracted using the RNAeasy
 
Ô
 
 kit (QIAGEN S.A., Courta-
boeuf, France), and polyadenylated mRNA was purified using
the Oligotex Direct mRNA kit (QIAGEN S.A.). This RNA was
then treated with RNAse-free DNAse I (Boehringer Mannheim,
Meylan, France) for 1 h at 37
 
8
 
C and repurified using the RNA-
easy
 
Ô
 
 kit, and the yield was quantified spectrophotometrically.
RT-PCR was conducted using 500 ng of RNA as described by
Kavasaki (37). As a positive control, human 
 
b
 
-actin RNA was ret-
rotranscribed and amplified in parallel for each sample. As a nega-
tive control, an identical amount of RNA was amplified without
being retrotranscribed. PCR was conducted for 35 cycles accord-
ing to the protocol described by Michelson et al. (38). Transcrip-
tion of polyadenylated RNA was performed by RT-PCR for
RANTES and MCP-1 at 48 and 72 h after HCMV infection us-
ing the following primers: RANTES sense, 5
 
9
 
 CGG GAT CCA
TGA AGG TCT CCG CGG CA 3
 
9
 
; RANTES antisense, 5
 
9
 
CGG AAT TCC TAG CTC ATC TCC AAA GA 3
 
9
 
; MCP-1
sense, 5
 
9
 
 GCC GCC CTT CTG TGC CTG CTG CTC ATA
GCA 3
 
9
 
; and MCP-1 antisense, 5
 
9
 
 GGG GTA GAA CTG TGG
TTC AAG AGG AAA AG 3
 
9
 
. Transcription analysis of cellular
CC chemokine receptors CCR1, CCR3, and CCR5 and polyA
RNA for CCR1 was performed using whole cell RNA extracted
and from uninfected cells and cells infected with HCMV for ei-
ther 4 or 24 h. Primers for these receptors were as follows: CCR-1
sense, 5
 
9
 
 AAGATTCTGCTAAGACGACC 3
 
9
 
;
 
 
 
antisense, 5
 
9
 
ATCACCTCCGTCACTTGC 3
 
9
 
;
 
 
 
CCR-3 sense, 5
 
9
 
 GAATGA-
CCATCTTCTGTCTCG 3
 
9
 
;
 
 
 
antisense, 5
 
9
 
 GAAGGATAGCC-
ACATTGTAGG 3
 
9
 
;
 
 
 
CCR-5 sense, 5
 
9
 
 CTGACATCTACCTG-
CTCAACC 3
 
9
 
; and antisense, 5
 
9
 
 GAAGATTCCAGAGAA-
GAAGCC 3
 
9
 
.
 
Results
 
Depletion of TNF-induced RANTES from Medium of
HCMV-infected Fibroblasts.
 
HCMV infection of HFF cells
induces RANTES production, but as the virus replication
cycle progresses, extracellular RANTES is no longer de-
tected, although RANTES transcription continues (38).
To see if cytokine-superinduced RANTES production is
similarly depleted from HCMV-infected cell medium, un-
infected and infected HFF cells were treated continuously
with TNF-
 
a
 
 for 24, 48, or 72 h and culture medium was
collected at the indicated intervals (Fig. 1). At each time in-
terval, cells were washed and re-fed medium with or with- 
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out TNF (5 ng/ml), as indicated in the legend to Fig. 1.
Uninfected, nontreated cells produced no detectable extra-
cellular RANTES throughout the observation period. In
contrast, RANTES production was induced by HCMV in-
fection at 24 h pi, but decreased to undetectable levels by
72 h pi (Fig. 1 
 
A
 
), in accordance with our earlier findings
(38). Medium from uninfected cells treated for 24 h with
TNF-
 
a
 
 contained 
 
z
 
200 pg/ml of RANTES (Fig. 1 
 
B
 
).
This production increased slightly after the removal of
TNF-
 
a
 
. When HCMV-infected cells were treated with
TNF-
 
a
 
 for 24 h (starting from the time of virus adsorption
to cells), the level of extracellular RANTES accumulation
within the 0–24 h period was 
 
z
 
20% higher than that pro-
duced by nontreated, infected cells (1,900 pg/ml compared
with 1,500 pg/ml). However, as a function of time after
infection, extracellular RANTES accumulation decreased
markedly in the medium of all infected cell cultures, drop-
ping to below 400 pg/ml. When TNF-
 
a
 
 treatment was
maintained for 48 or 72 h, RANTES accumulation in-
creased steadily in the medium of uninfected cells (Fig. 1,
 
C and D). From a baseline of 200 pg/ml after 24 h of treat-
ment, RANTES levels increased to 1,300 and 1,500 pg/ml
by 72 h when cells were continuously treated for 48 and
72 h, respectively. In contrast, in the medium of simi-
larly treated HCMV-infected cells, extracellular levels of
RANTES declined steadily from 1,950 pg/ml to z650 pg/
ml, a threefold decrease. This decrease was not attributable
to repression of RANTES transcription, as shown by RT-
PCR analysis of polyadenylated RNA from infected cells
(Fig. 2).
Depletion of Constitutively Produced MCP-1 from Medium of
HCMV-infected Fibroblasts. During the course of our stud-
ies, we observed that our HFF cells produced MCP-1 con-
stitutively (Fig. 2). Therefore, we asked whether HCMV
infection could also lead to the depletion of this constitu-
tively produced CC chemokine. Infection of HFF cells
with either pelleted AD169 virions or whole AD169 inoc-
ulum led to a 10- and 20-fold reduction, respectively, of
extracellular MCP-1 by 72 h pi (Table 1). This did not oc-
cur when fibroblasts were incubated with virus-free super-
natant or infected with heat- or UV-inactivated virus. Two
other human diploid fibroblast lines that we examined,
MRC-5 and WI-38, also produced MCP-1 constitutively.
Infection of both these lung fibroblasts with whole viral in-
oculum resulted in a 5–10-fold reduction in extracellular
MCP-1 levels by 48 h pi (data not shown). Analysis by
RT-PCR of polyadenylated RNA extracted from unin-
Figure 1. Uninfected and in-
fected cells were incubated with
TNF (5 ng/ml) from time 0 (rel-
ative to the start of infection) for
varying periods of time: A, no
treatment with TNF; B, treated
with TNF from 0 to 24 h; C,
treated with TNF from 0 to 48 h;
D, treated with TNF from 0 to
72 h. RANTES production was
measured in culture supernatants
collected from infected and un-
infected cells at the intervals in-
dicated in the x axis (0–24, 24–
48, and 48–72 h relative to the
start of infection or the begin-
ning of treatment). At each time,
cells were washed and re-fed
medium with or without TNF as
indicated. The experiment was
run in triplicate. Extracellular
RANTES (pg/ml) was quanti-
fied by ELISA.
Figure 2. Cells were infected with wild-type HCMV for the times in-
dicated (PI) or were uninfected (NI). Poly A RNA was extracted, reverse
transcribed, and amplified by PCR using primers specific for RANTES,
MCP-1, or actin. PC, positive control of the corresponding cDNA
cloned in pCDNA; NC, the negative control consisting of nonretrotrans-
cribed poly A RNA. Molecular weight markers were the 100-bp ladder.859 Bodaghi et al.
fected and HCMV-infected HFF cells demonstrated that
depletion of MCP-1 from culture medium was not due to
cessation of transcription (Fig. 2).
Measurement of Intracellular Levels of RANTES and MCP-1.
To determine if these chemokines could be detected intra-
cellularly, supernatants of uninfected and infected cells
were collected. The corresponding cells were incubated in
acid-glycine buffer to remove receptor-bound chemokine
followed by extraction of a cytoplasmic fraction (see Mate-
rials and Methods). RANTES and MCP-1 were measured
in duplicate supernatant/cytoplasm pairs by ELISA. At 24 h
pi (Table 2), when extracellular chemokine levels are high-
est, intracellular chemokine represented 32 and 17% of ex-
tracellular RANTES and MCP-1 levels, respectively. At 48 h
pi, the levels of intracellular chemokines were below the
level of detection by ELISA.
Chemokine Binding to HCMV-infected Cells. The HCMV
genome encodes three proteins with homology to CC type
chemokine receptors: UL33, US27, and US28 (39). To de-
termine when these genes may function during the course
of the viral replicative cycle, their expression in HCMV
strain AD169-infected HFF cells was examined by RNA
blot hybridization (Fig. 3). A previous study indicated that
each of these genes was expressed by late times pi (40). Our
analyses revealed that both UL33 (3.0–3.3 kb) and US28
(1.3 kb) transcripts are detected much earlier, by 8 h pi, and
increase in abundance to 72 h pi (i.e., early and late times
pi, respectively). In contrast, US27 (2.9 kb) RNA was de-
tected only at late times pi (i.e., 48–72 h pi). US27 RNA is
detected with the same probe used for US28, since the
transcript that initiates just upstream of US27 reads through
both US27 and US28 (40) (Fig. 3 B).
Of the three HCMV-encoded G protein–coupled CC
chemokine receptor homologues, only the US28 gene
product has been shown to be a functional chemokine re-
ceptor, and only in transfected cells (29, 30). These reports
indicated that, at least in the absence of other HCMV gene
products, the US28-encoded receptor could bind the CC
chemokines MIP-1a, MIP-1b, MCP-1, and RANTES. We
sought to extend these observations by examining the
binding of the CC chemokine, MIP-1a, to HCMV strain
AD169-infected HFF cells at 24, 48, and 72 h pi. (Fig. 4
A). Uninfected fibroblasts did not bind MIP-1a, whereas
binding to HCMV-infected cells was detected at all three
times, increasing from early (24 h) to late times (72 h) pi.
Indicative of specificity, this binding was reduced to back-
ground levels (i.e., 10–40-fold reduction) in the presence
of 400-fold excess unlabeled MIP-1a, similar to those lev-
els detected in uninfected cells. Thus, in both qualitative
and quantitative terms, the early-late binding kinetics of
chemokines to HCMV-infected cells coincides with the
early-late expression kinetics of the US28 transcription unit
(Fig. 3 B). Similar chemokine binding experiments were
performed using a recent clinical isolate of HCMV and
simian CMV. Specific MIP-1a binding to fibroblasts in-
fected with these CMVs was also observed (data not
shown). Thus, CC chemokine binding in cells infected
with at least primate CMVs is conserved and may be func-
tionally important.
To examine the breadth of CC chemokine binding in
HCMV-infected cells to the MIP-1a receptor, competition
binding studies were performed in the presence of 800-fold
excess unlabeled heterologous chemokines (Fig. 4 B). This
experiment indicated that the CC chemokines MIP-1b,
RANTES, MCP-1, and MCP-3 caused the displacement
of .95% of MIP-1a binding, and thus bind to the same
receptor as does MIP-1a. In contrast, MCP-2 did not
compete with MIP-1a, as indicated by ,5% displacement.
Furthermore, additional binding experiments indicated that
competition for the MIP-1a receptor in HCMV-infected
HFF cells by heterologous CC chemokines occurred in a
dose-dependent fashion as expected for receptor–ligand
interactions (data not shown). The relative affinity of
each chemokine for the MIP-1a receptor was estimated
based on the concentration of cold competitor required to
displace 50% of bound 125I-labeled MIP-1a. In these
Table 1. Extracellular Production of MCP-1 after HCMV 
Infection of Fibroblasts
Fibroblasts
Extracellular production of MCP-1
0–8 h‡ 8–24 h‡ 24–48 h‡ 48–72 h‡
pg/ml
Uninfected 5,615 11,840 9,938 10,879
Virus-free supernatant 10,016 10,738 10,972 12,131
Infected with:
UV-inactivated 9,906 10,572 10,889 10,555
Heat-inactivated 10,946 10,551 10,136 12,021
Pelleted virus 8,992 9,377 5,329 1,157
Whole inoculum 10,811 10,000 4,301 570
*Representative of two experiments.
‡Time intervals at which supernatants were collected. At each time in-
terval, cells were washed and re-fed growth medium.
Table 2. Measurement of Intracellular RANTES and MCP-1
Infection
RANTES MCP-1
Extracellular Intracellular Extracellular Intracellular
pg/ml pg/ml
none 0 0 2,306 94
AD169 994 320 2,423 418
At 24 h after infection, culture supernatants were collected and cells
were treated with glycine buffer to strip cell membranes of chemokines
before lysing. Concentrations of chemokine are expressed as picogram/
milliliter. All points represent the average of duplicate supernatant/cy-
toplasm pairs.860 Sequestration of CC Chemokines by Cytomegalovirus-infected Cells
experiments, unlabeled RANTES, MIP-1a, and MIP-1b
competed for binding to the MIP-1a receptor with ap-
proximately equal efficiency (z1 nM); MCP-1 and MCP-3
competed less well, requiring approximately fivefold higher
concentrations.
Construction and Characterization of Mutant HCMV Deleted
of Genes Encoding CC Chemokine Receptors. It was of in-
terest to determine whether US28, its related adjacent gene
(US27), or UL33 were responsible for either (a) the deple-
tion of CC chemokines from HCMV-infected cell super-
natants; or (b) the specific binding of CC chemokines to
HCMV-infected cells. For this purpose, insertion or dele-
tion mutants of the HCMV strain AD169 were constructed
by insertion of the 2.85-kb b-gluc expression cassette in
the US27 or US28 gene loci, as shown (Fig. 5, A–C).
RV91 has a disruption of the US27 gene; RV92 has dis-
ruption/deletion of US28; and RV101 is deleted of both
US27 and US28 (Fig. 5 B). The proper genomic organiza-
tion of these mutants was verified by both DNA and RNA
blot hybridization (data not shown). RV134 has an inser-
tion within the US9–US10 intergenic region and serves as
a pseudo wild-type control mutant (32). Single cycle growth
analyses (Fig. 5 D) indicated that all viruses grew with the
same kinetics, but RV92 had an z5–10-fold lower yield.
The slight yield impairment of RV92 is not due to the de-
letion of US28, since RV101 (deleted of both US27 and
US28) grows to levels similar to AD169 wild-type and
control RV134 viruses, but may be due to a positional ef-
fect of the marker gene insertion.
To determine if any of the disrupted or deleted genes in
these mutants were responsible for binding chemokines,
studies were performed in cells infected with mutant
HCMV at 72 h pi (Fig. 6), when chemokine binding to
wild-type infected cells is maximal (Fig. 4). HFF cells in-
fected with either of two independent identical isolates of
US28 deletion mutant RV92, designated RV92-2 and
RV92-15, failed to bind MIP-1a (Fig. 6 A). Binding of ra-
diolabeled MIP-1a to RV92-infected HFF cells was re-
duced to the background level detected in uninfected cells.
In a parallel experiment, immunoblot analyses of the
HCMV UL80 protease expression was used to confirm that
the late stage of the replicative cycle was reached in cells
infected with mutant and wild-type viruses (reference 36
and data not shown). Although the US28 gene is disrupted
by the b-gluc expression cassette insertion in RV92, the
upstream US27 transcription unit is also altered, since in
wild-type HCMV, US27 and US28 transcripts are 39 co-
terminal (Fig. 5 B and reference 40). The possible contri-
bution of US27 was addressed in binding experiments us-
ing US27 insertion mutant RV91-infected HFF cells (Fig.
6 B). RV91-infected cells bound MIP-1a to approximately
the same extent as did cells infected with either wild-type
strain AD169 or control insertion mutant RV134. Further-
more, RV101, a mutant deleted of both US27 and US28,
Figure 3. Kinetics of HCMV
UL33 (A) and US27/US28 RNA
(B) expression. Total cytoplasmic
RNA from uninfected (U) or
HCMV strain AD169-infected
HFF cells (multiplicity of infection
3) were isolated at the indicated
hour pi and analyzed by blot hy-
bridization. Riboprobes used for
each blot, as well as the expected
transcripts (40) are indicated in the
schematic drawing. T, transcrip-
tion initiation site; An, polyadenyl-
ation site; E, early kinetic class
transcript;  L, late kinetic class tran-
script.861 Bodaghi et al.
also failed to bind MIP-1a. In contrast, as an additional
control, cells infected with RV11, a mutant with a b-gluc
insertion replacing an NH2-terminal portion of UL33 with
unimpaired growth kinetics (Jones, T.R., unpublished
data), retained full ability to bind MIP-1a (Fig. 6 B). By
RNA blot hybridization, each of the HCMV mutants that
bound the CC chemokine MIP-1a at late times pi had an
intact US28 transcription unit which was expressed at
wild-type levels (data not shown). Therefore, the data are
indicative that the US28-encoded receptor is in large part
responsible for CC chemokine binding in HCMV-infected
cells.
Role of Receptors Encoded by US28 in the Depletion of
RANTES and MCP-1 after Infection. Three human cellu-
lar receptors, CCR1, CCR3, and CCR5, have been
shown to bind CC chemokines, including RANTES and
MCP-1 (41). However, by RT-PCR, we were unable to
detect any transcripts for CCR3 and CCR5 in total RNA
or of CCR1 in the polyadenylated fraction from either un-
infected or HCMV-infected HFF cells (data not shown).
Therefore, the early-late expression kinetics of the HCMV
US28-encoded receptor (Fig. 3 B), in conjunction with its
capability to bind RANTES and MCP-1 (Figs. 4 and 6),
suggest that it may play a role in the depletion of these
chemokines from the media of HCMV-infected cells (Ta-
ble 1 and Fig. 1). To directly study the HCMV encoded
CC chemokine receptor homologues in chemokine deple-
tion, the extracellular levels of RANTES and MCP-1 in
the culture medium of HFF cells infected with each of the
CC chemokine receptor mutants were examined (Fig. 7).
Infection with RV92 or RV101, both US28 deletion mu-
tants, failed to lead to the extensive depletion of either
RANTES (Fig. 7 A) or MCP-1 (Fig. 7 B) from the culture
medium. In contrast, infection with RV91 led to a marked
reduction of extracellular RANTES and MCP-1, almost
similar to that observed in cells infected with wild-type
HCMV. Comparable effects on extracellular RANTES
and MCP-1 levels were observed in other fibroblasts,
MRC-5 and WI-38, infected with these mutant viruses
(data not shown). Consistent with its ability to bind CC
chemokines, these results strongly suggest that US28 plays a
major role in the depletion of CC chemokines from the
extracellular media of HCMV-infected cells.
Internalization of Exogenously Added RANTES by Infected
Cells. Previously, we demonstrated by immunofluores-
cence that RANTES accumulated within HCMV-infected
cells concomitant with its depletion from culture medium.
Additional experiments indicated that this was not due to
soluble proteases (38). These observations raised the fol-
lowing possibilities: (a) RANTES or MCP-1 is being re-
tained intracellularly by HCMV-encoded receptors as these
chemokines are synthesized and/or (b) newly synthesized
chemokines are released from the infected cell, but that
HCMV-encoded cell receptors expressed at the cell surface
Figure 4. Time course and specificity of MIP-1a
receptor expression. (A) 125I-labeled MIP-1a bind-
ing to uninfected (UNINF) or HCMV strain
AD169-infected HFF cells was examined at the in-
dicated time pi, in either the absence or presence of
excess unlabeled MIP-1a ( h 1 MIP-1a) at a final
concentration of 100 nM. cpm of bound radiolabeled
MIP-1a are given above each bar. (B) Percentage
of displaceable binding of 125I-labeled MIP-1a us-
ing the indicated unlabeled chemokine (200 nM fi-
nal concentration) in infected HFF cells at 72 h pi.
Figure 5. Genome organization and growth of HCMV mutants. The
organization of the HCMV genome (A) and the BamHI-S fragment (B),
which contains the US27 and US28 genes, are shown in the schematic
drawing. In B, the US27 and US28 transcripts are shown, as well as the
sites of the b-gluc expression cassette insertions in RV91, RV92, or
RV101. The arrowhead is the site of a point insertion (RV91) and dark
rectangles indicate deletions (RV92 and RV101). (C) Schematic drawing
of the 2.85-kb b-gluc expression cassette used in the construction of
HCMV mutants. (D) Single cycle growth analysis of HCMV mutants.862 Sequestration of CC Chemokines by Cytomegalovirus-infected Cells
are undergoing continual binding and rapid internalization
of the chemokines.
To examine the possibility that chemokines released
from HCMV-infected cells may be subsequently bound by
HCMV-encoded receptors, several experiments were per-
formed. The first experiment was based on the observation
that chemokine expression can be induced by HCMV in-
fection of fibroblasts and accumulates in the extracellular
medium at 48–72 h pi of cells infected with US28 mutants
(Fig. 7). Conditioned medium collected at 72 h pi from
cells infected with US28-negative mutants or US28-posi-
tive virus infected cells as control was used as a cold com-
petitor in an MIP-1a–binding assay to wild-type HCMV-
infected cells (Table 3). Relative to fresh medium, media
conditioned on cells infected with US28-negative mutants
inhibited 48% of total MIP-1a binding. In contrast, media
conditioned on US28-positive cells inhibited MIP-1a
binding by ,5%.
In a second experiment, exogenous rRANTES was
added to HCMV-infected HFF cells to see if it would be
removed from the medium. At 48 h pi, medium was col-
lected and cells were washed with PBS, then treated with a
low pH glycine buffer to strip the membrane of any
chemokine (34). Exogenous rRANTES was then added to
culture medium and cells were incubated for different
times at 378C before measuring the amount of RANTES
Figure 6. MIP-1a binding by cells infected with HCMV mutants. Uninfected or HCMV-infected HFF cells (multiplicity of infection 2.5) were analyzed
for their ability to bind 125I-labeled MIP-1a at 72 h pi. RV92-2 and RV92-15 are independent isolates containing the identical US28 deletion. In some exper-
iments, excess unlabeled MIP-1a (200 nM final concentration) was used (AD1691MIP-1a). cpm of bound radiolabeled MIP-1a are given above each bar.
Figure 7. (A) RANTES expressed in picogram/milliliter or (B) MCP-1
expressed in nanogram/milliliter were measured by ELISA in superna-
tants collected at 0–24 h (black bars), 24–48 (white bars), and 48–72 h (gray
bars) after infection from either uninfected cells (NF) or cells infected with
wild-type or mutant HCMVs: AD (wild-type), RV91 (DUS27), RV92
(DUS28), RV101 (DUS27/DUS28). At each interval, cells were washed
and re-fed growth medium.
Table 3. Adsorption of MIP-1a from Conditioned Media
Conditioned
medium source
Cpm MIP-1a
bound
(standard deviation)
Percentage of
reduction of
MIP-1a binding
None (fresh medium) 27,164 (1,750) None
US28-positive cells 25,962 (4,362) 4.5
US28-negative cells 14,090 (1,802) 48.2
Target cells in the MIP-1a binding assay were HCMV strain AD169-
infected HFF cells at 72 h pi. The binding assay was done as described
in Materials and Methods using 0.25 nM of radiolabeled MIP-1a per
well, except that 0.125 ml of conditioned medium replaced an equal
volume of cold binding buffer. No attempt was made to remove
chemokines from the infected cell membranes before the initiation of
the binding assay. Each data point represents the mean and standard de-
viation derived from three to four plates, as follows: US28-positive in-
fected cell–conditioned medium was from one plate each of HFF cells
infected with wild-type strains AD169, RV134, RV91, and RV11.
US28-negative infected cell–conditioned medium was from cells in-
fected with RV92 (one plate) and RV101 (two plates).863 Bodaghi et al.
remaining in the medium. Incubation of HCMV-infected
fibroblasts with 600 pg/ml of rRANTES for 30 min or 3 h
resulted in a 12 and a 72% reduction, respectively, of the
exogenously added chemokine. Similar experiments were
carried out on cells infected for 72 h. An average (two ex-
periments run in duplicate) of 59% of added rRANTES
disappeared from the medium of infected cells after a 3-h
adsorption period at 378C. In all experiments, RANTES
was not detected in the medium sampled before starting
the adsorption period (i.e., before the addition of exoge-
nous rRANTES). Taken together, these experiments indicate
that chemokines synthesized and released from HCMV-
infected cells can bind to, at least, the US28-encoded re-
ceptor on the surface of these cells.
It is known that when a chemokine contacts its receptor,
both are internalized and ligand is released from the recep-
tor, which then recirculates to the cell surface (42). To de-
termine whether extracellular RANTES was being inter-
nalized from the cell surface after receptor binding, uninfected
cells or HCMV-infected cells (at 48 h pi) were incubated
with RANTES-B for 3 h at 378C, washed to remove cell
surface (noninternalized) chemokine, then analyzed by im-
munoblot using peroxidase-labeled streptavidin, as described
in Materials and Methods (Fig. 8). The results demonstrate
that RANTES-B was efficiently internalized by cells in-
fected with wild-type HCMV, less so by cells infected with
the mutants RV91 and RV92, and not at all by RV101-
infected cells or uninfected fibroblasts.
Discussion
After primary infection, HCMV, like other herpesvi-
ruses, establishes itself in a latent or persistent state and re-
sides in its host for the remainder of the host’s lifetime (43).
To facilitate this state, HCMV has several means designed
seemingly to avoid elimination of infected cells by the im-
mune surveillance system. HCMV encodes at least four
genes whose products play a role in the downregulation of
surface expression of HLA class I molecules (9, 10, 18–23).
In addition, HCMV infection can interfere with normal
cytokine production (44) and upregulate production of
such lymphostatic factors as TGF-b (45) and IL-1Ra (46).
However, the HCMV genome also carries three genes
with homology to CCRs (UL33, US27, and US28; refer-
ence 39). The role of these receptors in the life cycle of
human HCMV in vivo has not yet been determined.
HCMV UL33 was shown to be a virion envelope protein,
but its function remains unknown (27). The murine cy-
tomegalovirus homologue of HCMV UL33, designated
M33 (47), may play a role in the establishment of latency of
murine HCMV in salivary glands (48). Unfortunately, mu-
rine HCMV does not possess homologues of US27 and
US28. Of the HCMV CCR homologues, only US28 has
been shown to be functional to date. In transfected mam-
malian cells, US28 mobilizes Ca21 in response to RANTES,
MIP-1a, and MCP-1 (29, 30); in Hela and astrocytoma
cells, it can act as a coreceptor for HIV entry (49). How-
ever, these studies do not shed light on the function of
US28 in the context of HCMV infection.
In the context of HCMV-infected cells, we show here
that the product of the HCMV US28 gene plays a promi-
nent role in binding and sequestering of extracellular CC
chemokines. Through the use of specific HCMV gene dis-
ruption/deletion recombinant mutants, the US28-encoded
receptor was shown to be the only MIP-1a binding recep-
tor expressed in HCMV-infected cells. Cells infected with
a US27 mutant (RV91) or a UL33 mutant (RV11), but not
a US28 mutant (RV92) or a US271US28 mutant (RV101),
retained ability to bind the CC chemokine MIP-1a. In
conjunction with our inability to detect CCR polyadenyl-
ated transcripts in infected cells, this observation effectively
rules out the possibility that HCMV infection induces ex-
pression of cellular MIP-1a receptors. In addition to MIP-1a
binding in HCMV-infected cells, the US28-encoded re-
ceptor binds other CC chemokines, including MIP-1b,
RANTES, and MCP-1, consistent with the binding ob-
served in US28-transfected cells (29, 30). We have ex-
tended these observations in that the US28-encoded re-
ceptor also binds MCP-3, but not MCP-2, both CC
chemokines. Interestingly, at the amino acid level MCP-2
is highly homologous to MCP-1 and MCP-3 (62 and 60%,
respectively; reference 41).
Cell surface expression of the US28-encoded receptor
results in the depletion of CC chemokines, especially
RANTES and MCP-1, from the medium of HCMV-
infected cells. Cells infected with mutants that expressed
the other putative chemokine receptors, US27 or UL33
(i.e., RV101 and RV92), but lacked US28 expression,
failed to efficiently deplete chemokines from the medium
(Fig. 7). Furthermore, cells infected with viruses that ex-
pressed US28 internalized exogenous RANTES, whereas
uninfected cells or cells infected with RV101, deleted of
both US27/US28, failed to internalize added RANTES
(Fig. 8). Taken together, these data indicate that UL33,
which is present and transcribed at wild-type levels in cells
infected with RV101 (data not shown), does not play a role
in the sequestration of RANTES or MCP-1.
Figure 8. Fibroblasts infected for 48 h with wild-type (AD) or mutant
HCMVs (RV101, RV92, RV91) were washed with PBS, incubated for 3
min at room temperature with low pH glycine buffer to strip membranes
of chemokine, and then incubated with biotinylated RANTES (100 nM)
for 3 h at 378C. Cells were then washed again with PBS, treated with
low-pH glycine buffer, trypsinized, and extracted in a high salt buffer.
Extracts were separated in 15% SDS-PAGE and transferred to nitrocellu-
lose. After saturation with 3% gelatin/1% BSA in PBS/0.1% Tween 20,
blots were incubated with peroxidase-labeled streptavidin (1:400) and de-
veloped using a chemiluminescence technique for 5 s. RANTES-B
(Rantes-B, 125 ng) was run in parallel. AD 5 infected with wild-type
HCMV; RV91 5 infected with DUS27 mutant HCMV; RV92 5 in-
fected with DUS28 mutant HCMV; RV101 5 infected with DUS27/
DUS28 mutant HCMV; NF 5 uninfected cell extract. Representative of
two experiments.864 Sequestration of CC Chemokines by Cytomegalovirus-infected Cells
Remarkably, the ability to internalize RANTES did not
strictly correlate with US28 expression. Cells infected with
US28 mutant RV92 or US27 mutant RV91 internalized
RANTES, although to a lesser extent than cells infected
with wild-type HCMV. Although it is clear from our ex-
periments that the US28-encoded receptor functions to
bind and internalize CC chemokines in HCMV-infected
cells, the US27-encoded receptor may also contribute to
these processes. Thus, it is possible that US28 is not the
only HCMV-encoded receptor that binds and internalizes
RANTES. The US27-encoded receptor may also bind/in-
ternalize RANTES, but has differential affinity for MIP-1a
(i.e., the US28-encoded receptor, but not the US27-
encoded receptor, binds MIP-1a). We are currently inves-
tigating the possibility that the US27-encoded receptor is a
low affinity receptor for some CC chemokines.
We propose that a role for the chemokine receptors ex-
pressed in HCMV-infected cells may be the ability to se-
quester chemokines from the extracellular milieu. We dem-
onstrated recently (38), and confirm here, that chemokines
accumulate intracellularly in HCMV-infected cells. This
appears to be partially due to continual internalization from
the exterior, as shown here, since in HCMV-infected cells
(a) exogenously added RANTES disappeared from cell
medium and (b) added biotinylated RANTES was found
intracellularly. We cannot exclude the possibility that en-
dogenously produced chemokines may also be sequestered
intracellularly without ever being secreted. When exposed
to ligand, the US28-encoded receptor in transfected cells
can initiate a transmembrane signal that results in second
messenger signaling, including calcium flux (29, 30). This
may also occur in HCMV-infected cells and alter cell phys-
iology, thereby affecting replication of the virus. However,
the presence or absence of chemokines had no detectable
effect on the growth properties of HCMV wild-type in fi-
broblasts compared with US271US28 mutant RV101
(Jones, T.R., unpublished data). Additionally, Pertussis
toxin, which interferes with signaling of some cellular
chemokine receptors (41, 50), likewise had no effect on
growth of these viruses (Jones, T.R., unpublished data).
Induction and disappearance of RANTES are two sepa-
rable phenomena. Induction occurs independently of an
active CMV genome upon contact/penetration of virus
into fibroblasts, as illustrated by the fact that UV-inacti-
vated virus induces RANTES production. Induction could
therefore be due to contact of viral elements with cell
membranes and/or introduction of viral proteins and DNA
into the cell. Hence, even an abortive infection in the ab-
sence of viral genome expression might induce production
of RANTES, which could in turn induce recruitment of
lymphocytes.
On the other hand, disappearance of RANTES as infec-
tion progresses does depend on viral genome expression,
since it does not occur when cells are infected with UV-
inactivated virus. Hence, when CMV genome expression
progresses and US28 and US27 are encoded, CC chemo-
kines, whether induced by virus contact (RANTES) or not
(MCP-1), are sequestered from the infected cell environ-
ment. Such sequestration could prevent not only lymphocyte
recruitment, but also stimulation of effector mechanisms of
lymphocytes in the neighborhood of infected cells. The ca-
pacity of HCMV infected cells to sequester CC chemo-
kines could potentially perturb local immune responses by
altering their concentration in the proximal extracellular
milieu. CC chemokines have been shown to play a role in
inflammation and infiltration by lymphocytes, monocytes,
eosinophils, and basophils at disease sites (41, 51). They are
also important in activating the cytotoxic potential of CD81
lymphocytes (52, 53) and NK cells (1). Thus, this sequestra-
tion could have a negative effect on the attraction of leuko-
cytes to sites of CMV infection and on the immune func-
tion of leukocytes in the environment of infected cells.
Hence, this CMV strategy would help the virus to go un-
noticed and thereby escape immune surveillance.
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